Can existing drugs effectively treat new coronavirus infections? See what the scientists say!

!--webeditor:page title" -- March 29, 2020 // -- Drugs used to treat COVID-19 may not be available in pharmacies for months, even years, but thousands of patients are now treated in hospitals and clinics, so clinicians are looking for drugs that have been approved to treat other diseases to effectively treat COVID-19.
, HIV and arthritis do not seem to have much in common with SARS-CoV-2, but the drugs developed for these diseases show some hope in the fight against respiratory diseases in an pandemic.
details of some of the drugs tested, the researchers wanted to see if they were effective against COVID-19.
Photo Source: CC0 Public Domain chloroquine, a synthetic version of quinine that has been used to treat malaria patients for nearly a century, is a natural compound that has been extracted from the bark of the golden chicken tree since the early 17th century.
researcher Karla Satchell says chloroquine works by reducing the efficiency of the virus's entry into cells, thereby reducing the speed at which the virus replicates.
to fight malaria, the drug mainly helps to poison the digestive system of some of the blood parasites of the malaria parasite genus, which are transmitted to humans through infected mosquitoes.
COVID-19 is a disease caused by a new coronavirus, but the researchers believe chloroquine can help patients with the new disease by slowing the spread of the virus, essentially by reducing the virus's ability to exploit certain parts of the cell to get itself to the target.
Currently, researchers are conducting about 24 clinical trials in China to test whether chloroquine is effective in treating SARS-CoV-2 infections, and early results suggest that it appears to slow the replication of the virus, while some researchers believe its ability to regulate host immune system behavior may help slow down so-called cytokine storms, a deadly body overreaction that can lead to organ failure.
chloroquine has several advantages and is known to be very safe for humans, although overuse can lead to drug poisoning and is cheap, and has been endorsed by U.S. President Donald Trump, who recently asked the FDA to analyze whether chloroquine is effective in treating COVID-19, which in preclinical studies can effectively treat a variety of viral infections such as SARS, MRES and HIV.
Hydroxychloroquine, which we can guess is closely related to chloroquine, a potentially less toxic malaria drug metabolite that can be used to treat certain autoimmune diseases, such as lupus and rheumatoid arthritis, could work by interfering with communication between immune system cells, and like chloroquine, hydroxychloroquine may help slow cell-factor storms.
Clinicians are currently using the drug to test patients, arguing that hydroxychloroquine may also help if chloroquine helps, and the results of a recent trial appear to support this theory, with at least seven clinical trials currently conducted in China; Jakub Tolar says we'll know in 90 days whether hydroxychloroquine is effective in treating COVID-19 patients, and early clinical studies in China by researchers are promising, finding that hydroxychloroquine is effective in suppressing SARS-CoV-2 infections in the lab.
Photo Source: tasnimnews.com, like chloroquine, which is safe to use in human bodies and has been on the market since the 1950s, asked the FDA to begin research into whether chloroquine drugs, including hydroxychloroquine, are effective in treating COVID-19 patients, and six recently underwent a combination of hydroxychloroquine and azithromycin.
combination of kaletra and litonave, two antiviral drugs that can be used to fight HIV, is now widely used and several clinical trials are under way around the world, both of which are Protease inhibitors, when used in a combined way, have different but complementary effects; lopinave effectively inhibits proteins important for HIV replication in viral enzyme cutting; and litonave enhances the concentration of lopinave in cells.
Now researchers want to know if this combination of drugs can interfere with the viral life cycle of SARS-CoV-2 in a similar way; in a recent study published in the international journal New England Journal of Medicine, researchers found that the combination appeared to be treating severe COVI There is no benefit in D-19 patients, and while this is not a good thing for the drug's prospects, researchers admire this courageous attempt, but it is important to note that this is only one study, and that other clinical trials may eventually provide further insights.
Remdesivir, developed by Gilead Sciences to fight Ebola virus infection, is not proven to be effective by researchers, but in cell line and limited animal trials, researchers have shown that Redsivir has some effect in treating MERS and SARS, which are diseases caused by coronaviruses, so researchers believe that Redsivir may also be used to treat COVID-19.
researchers don't know exactly how Redsivir works, but a recent study showed that Redsyvirus appears to be effective in blocking the replication of viral RNA during coronavirus replication.
A recent case study in the journal New England Journal of Medicine showed that after the first case of COVID-19 in the United States worsened, clinicians gave patients Redsyvir, and then the next day the patient's symptoms were significantly reduced and the disease recovered, so it is not clear to researchers whether the drug is effective in treating COVID-19.
of ongoing clinical trials may provide some answers, and several institutions, including the NIH, have begun clinical trials.
Although Redsyvir can only be used to treat some COVID patients, the researchers do not have solid evidence that it improves clinical outcomes in patients, and late-stage clinical trials may provide some evidence that the drug can actually be effective.
!--/ewebeditor:page--!--ewebeditor:page title"---Picture: northcarolinahealthnews.org Losartan chloraten is a high blood pressure to go Blood pressure can be lowered by inhibiting hormones called angiotensins from being combined with a subject on the blood vessels to relax the blood vessels; the researchers speculate that chlorosatan may be able to help treat PATIENT-19 patients because it is an angiotensin-blocking agent that blocks the virus from entering cells.
the drug is the perfect combination of three therapies that University of Minnesota researchers are conducting in clinical trials, but researchers have not yet begun recruiting subjects for clinical trials, according to the NIH.
Other treatments researchers say re-using drugs already on the market, or at least proving safe, is the first step in the fight against the new coronavirus, but these drugs may be a "blunt instrument";
researchers, Satchell and his team are delving into the proteins and other structures of the virus, hoping to develop new drugs to fight viral infections, and are currently working on the molecular machines needed to target viral viruses for replication.
She says that if you walk up to a machine and put a screwdriver somewhere, the machine will be forced to stop working, but the key is to figure out where the screwdriver was inserted and what it should look like, which may be the key we're looking for.
the good thing about doing this is that we can get a drug, but the downside is that it has to start from scratch and it may take longer to make a drug available to the public.
Fortunately, scientists can also use viruses such as MERS and SARS for research, and because SARS-CoV-2 is very similar in genomics to MERS and SARS viruses, researchers may be able to quickly and efficiently study the pathogenic mechanisms of SARS-CoV-2;
If the researchers had found effective drugs, then perhaps we could have treated COVID-19 effectively, and even if the pathogens that cause future outbreaks are slightly different, the work on SARS-CoV-2 may be useful.
, the researchers said, 'I hope we can learn from this outbreak, and even after the crisis has disappeared, the research will continue.'
() Reference: Coronavirus drugs: Where we are and what we knowby Amina Khan !--/ewebeditor:page--.